Cancer patient preferences are for a shorter duration of adjuvant chemotherapy, with Australian research showing many are not prepared to undergo longer duration of chemotherapy unless the treatment confers a big survival benefit. The finding comes from a study of Australian patients enrolled in the SCOT trial, a randomised phase 3 trial of three months ...
Patients expect substantial benefits to justify longer duration of adjuvant chemotherapy
By Sunalie Silva
1 Jul 2021